[An update on the clinical and pathogenetic value of a lymphocyte subpopulation study in systemic lupus erythematosus].
Systemic lupus erythematosus (SLE) is an entity with multiple clinical signs due to a basic immunoregulation disorder with an unbalance between humoral and cellular components of the immunological response. Its course of evolution is characterized by frequent exacerbations and remissions and the search for new activity markers of the disease is an ongoing activity. During the past years, phenotypical studies of the immunological system cells have been incorporated to the effort of establishing clinical-immunological correlations and obtaining objective parameters useful for the clinical and therapeutical management of a disease as variable as the SLE. Several disorders among lymphocitary populations have been described in the SLE; however, the published data are sometimes controversial, given the clinical and serological heterogenicity of the disease.